First Author: L.Cordoves SPAIN
Co Author(s): J. Abreu P. Abreu F. Holz
Back to previous
Several treatments have been proposed for chronic central serous chorioretinopathy, but there are no clear guidelines regarding their use. This case report highlights how complicated this treatment may become in resilient cases.
Opthalmology service. University hospital.
60 year old patient with long standing central serous chorioretinopathy that was successively treated with mineralocorticoid receptor antagonists (spironolactone, eplerenone), photodynamic therapy - PDT (half-fluence, full-fluence) and anti-VEGF agents (aflibercept). Best corrected visual acuity, optical coherence tomography, fluorescein angiography and indocyanine green angiography were used to monitor the response and determine the treatment steps.
Aldosterone inhibitors didn't induce a fluid reduction. Half fluence PDT produced a short lived temporary remission. Aflibercept appeared to be useful initially, but its effect became shorter and shorter with succesive injections. Only full-fluence PDT with simultaneous aflibercept injection and monthly injections thereafter has produced a lasting remission.
Although central serous chorioretinopathy is often considered a benign disease, its chronic form can pose a treatment challenge, as this case report may help illustrate.